Letermovir (PREVYMIS® licensed to MSD, tradename of Merck & Co., Inc., Rahway, N.J., USA) is a pioneering antiviral agent first approved by the FDA in 2017. It is indicated for the prevention of cytomegalovirus (CMV) infection in adult CMV-seropositive recipients of allogeneic hematopoietic stem cell transplants (HSCT) and kidney transplants. PREVYMIS® is now available in over 60 countries, including the EU, Canada, Japan, and China, and continues to achieve robust annual revenue growth.

Recently, the FDA extended PREVYMIS®’s approval to include the prevention of CMV disease in CMV-seropositive donor/CMV-seronegative recipient kidney transplant patients. Additionally, it has received approval in Japan for use in patients receiving solid organ transplants, further expanding its global impact in transplant care.